LGC SeraCare's SARS-CoV-2 Quality Solutions to now include the S gene
MILFORD, Massachusetts, May 5, 2020 -- In response to the critical need for accurate testing to combat the COVID-19 pandemic, LGC SeraCare continues to innovate and expand their novel AccuPlex™ SARS-CoV-2 Quality Solutions in support of improved diagnostic assay development and testing. The newly launched Version 2 Verification Panel, and Reference Material Kit, offer expanded genome coverage over the products first launched in March to now include the S gene region. As testing priorities shift from molecular to serological, LGC SeraCare also plans to expand their product offering to antibody controls in continued support of public health efforts against COVID-19.
LGC SeraCare’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process, quality control solutions that challenge the entire PCR test procedure, making them the preferred alternative to infectious materials. Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance.
Michael Sweatt, Executive Vice President, LGC SeraCare, stated: “AccuPlex technology offers an urgently needed tool supporting assay installation and verification, and daily performance monitoring, in support of a growing footprint of available testing laboratories, and to meet an ever-increasing testing demand. LGC is committed to providing quality measurement tools to support in vitro diagnostic assay developers and clinical laboratories to help ensure accurate and reliable patient test results.”
To learn more about these products, including details on the SARS-CoV-2 target sequences, please visit the LGC SeraCare website.
Notes for editors
About LGC Clinical Diagnostics
LGC’s Clinical Diagnostic Business Unit exists within the LGC’s Standards Division and is comprised of two operating entities - SeraCare Life Sciences and Maine Standards Company. We are in vitro diagnostic (IVD) manufacturers of clinical diagnostic quality solutions to the extended life science industry.
Our 225+ employees operate FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland and support diagnostic professionals in laboratories across the globe. We partner with IVD developers, pharmaceutical, CRO and academic institutions to share our expertise and resources in clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics.
We are committed to improving patient healthcare by offering products and services that support accurate and reliable diagnostic results.
About LGC
LGC is an international leader in the extended life sciences sector, including human healthcare, agri-food & the environment. LGC provides a comprehensive range of reference materials, proficiency testing schemes, and genomics reagents, as well as research and measurement services. Its scientific tools and solutions enable organizations to advance research, develop new products and form an essential part of their quality and compliance procedures.
LGC’s 3,150 employees include internationally recognized scientists who are experts in their field. Headquartered in London, it operates out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.
For more information, please visit the website or contact:
Eric Morreale
Director of Marketing
LGC Clinical Diagnostics
emorreale@seracare.com
+ 1 508-244-6455
https://digital.seracare.com/sars-cov-2